Summarizing the current state of pricing and coverage for GLP1s in the US with @rachelsachs.bsky.social in @nejm.org this week!
Read it before things change (again)!
www.nejm.org/doi/full/10....
The Trump administration’s agreements regarding glucagon-like peptide 1 receptor agonists
could reduce prices and improve access for some patients — and lead to substantial
additional spending.